SCHEMBL12907210

SCHEMBL12907210

CC(C)Cc1ccc(-c2ccc3c(N)n[nH]c3c2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 2/20 0.60
PDPK1 O15530 8/20 0.59
AURKB Q96GD4 4/20 0.51
AURKA O14965 3/20 0.51
TGFBR1 P36897 3/20 0.51
ABL1 P00519 5/20 0.49
BCR P11274 5/20 0.49
ROCK1 Q13464 2/20 0.49
MKNK2 Q9HBH9 2/20 0.49
CDC7 O00311 1/20 0.49
PLK4 O00444 1/20 0.49
DCLK1 O15075 1/20 0.49
MAPK13 O15264 1/20 0.49
DAPK3 O43293 1/20 0.49
DYRK3 O43781 1/20 0.49
ROCK2 O75116 1/20 0.49
PRKD3 O94806 1/20 0.49
MAP4K4 O95819 1/20 0.49
NTRK1 P04629 1/20 0.49
CDK1 P06493 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12907184 0.88 JAK2 (0.62) JAK2PDPK1AURKBROCK1MKNK2
SCHEMBL12907431 0.85 PDPK1 (0.44) JAK2PDPK1AURKBABL1BCR
SCHEMBL6478485 0.83 JAK2 (0.66) JAK2PDPK1AURKBAURKATGFBR1
SCHEMBL27623383 0.81 JAK2 (0.68) JAK2PDPK1AURKBAURKATGFBR1
SCHEMBL12907252 0.80 JAK2 (0.66) JAK2PDPK1AURKBAURKATGFBR1
SCHEMBL2667981 0.78 JAK2 (0.57) JAK2PDPK1AURKBROCK1MKNK2
SCHEMBL6479941 0.78 JAK2 (0.72) JAK2PDPK1AURKBAURKATGFBR1
SCHEMBL421269 0.77 JAK2 (0.77) JAK2PDPK1AURKBAURKATGFBR1
SCHEMBL3361070 0.76 JAK2 (1.00) JAK2PDPK1AURKBAURKATGFBR1
SCHEMBL12907241 0.76 JAK2 (1.00) JAK2PDPK1AURKBAURKATGFBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7872039-B2 N-3-chlorobenzyl-3-amino-1H-indazole-5-carboxamide; 3-aminoindazoles; glucocorticoid-depedent kinase (SGK) inhibitors; SGK-induced diseases; diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, fibrosis; inflammatory agents MERCK PATENT GESELLSCHAFT (DE) 2011-01-18 US disclosed
US-7872039-B2 N-3-chlorobenzyl-3-amino-1H-indazole-5-carboxamide; 3-aminoindazoles; glucocorticoid-depedent kinase (SGK) inhibitors; SGK-induced diseases; diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, fibrosis; inflammatory agents MERCK PATENT GESELLSCHAFT (DE) 2011-01-18 US disclosed
EP-1765788-B1 3-AMINOINDAZOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SGK-ASSOCIATED DISEASES MERCK PATENT GMBH (DE) 2009-06-03 EP disclosed
US-20070232620-A1 3-Aminoindazoles MERCK PATENT GMBH (DE) 2007-10-04 US disclosed
US-20070232620-A1 3-Aminoindazoles MERCK PATENT GMBH (DE) 2007-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232620-A1 3-Aminoindazoles SGK3, SGK1, SGK2 JAK2 562/4885PDPK1 118/4885AURKB 323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.